Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab + TAS-102 in Advanced Gastric/GEJ Cancer (RE-ExPEL)
NCT04517747Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Oct 2020
- Primary completion
- Jan 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ramucirumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Institut für Klinische Krebsforschung. Started Oct 2020; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04517747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04517747.